ARTV
Artiva Biotherapeutics, Inc.
Key Financials
Operating Income
$-89810000
↓ 33.5%
Revenue
$0
↓ 100.0%
Net Income
$-83865000
↓ 28.3%
Total Assets
$130.9M
↓ 37.5%
EPS (Diluted)
$-3.43
↑ 41.0%
Cash & Equivalents
$26.7M
↓ 33.6%
Total Liabilities
$21.0M
↓ 8.6%
Operating Cash Flow
$-76751000.00
↓ 39.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 3/10/2026 | View on SEC |
| S-8 | 3/10/2026 | View on SEC |
| 10-K | 3/10/2026 | View on SEC |
| 8-K | 3/10/2026 | View on SEC |
| 3 | 2/24/2026 | View on SEC |
| 8-K | 2/24/2026 | View on SEC |
| 4 | 2/19/2026 | View on SEC |
| 3 | 2/19/2026 | View on SEC |
| 8-K | 2/19/2026 | View on SEC |
| 4 | 2/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ARTV |
| Company Name | Artiva Biotherapeutics, Inc. |
| CIK | 1817241 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 267-4467 |